Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DZD9008 plus bevacizumab in EGFR-mutant advanced non-small cell lung cancer
CTR20223245Phase 2Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunvozertinib and bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity, Adverse events and 1 more. Started Dec 2022; status: active.
02
Drugs
sunvozertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20223245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223245.